Eversept Partners, LP Adagio Therapeutics, Inc. Transaction History
Eversept Partners, LP
- $1.29 Billion
- Q3 2025
A detailed history of Eversept Partners, LP transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Eversept Partners, LP holds 2,047,265 shares of ADGI stock, worth $6.78 Million. This represents 0.52% of its overall portfolio holdings.
Number of Shares
2,047,265Holding current value
$6.78 Million% of portfolio
0.52%Shares
1 transactions
Others Institutions Holding ADGI
# of Institutions
82Shares Held
153MCall Options Held
244KPut Options Held
167K-
Janus Henderson Group PLC London, X025.4MShares$84 Million0.04% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct20.3MShares$67.2 Million0.13% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx19MShares$62.8 Million0.93% of portfolio
-
Ra Capital Management, L.P. Boston, MA17.1MShares$56.7 Million0.97% of portfolio
-
Mithril Ii Gp LP Austin, TX11.2MShares$37.2 Million19.18% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...